Ahsan Bhatti, Superintendent Pharmacist at licensed UK online pharmacy Quick Meds, explains what the newly-approved Wegovy tablet could mean for patients considering non-injectable weight loss treatments.
The approval of the first oral GLP-1 weight loss treatment in the UK marks a significant shift in how obesity may be managed in the years ahead. Until now, medicines such as Wegovy have only been available as injections. The arrival of a tablet version changes that landscape, offering a new option for both patients and prescribers.
The Medicines and Healthcare products Regulatory Agency (MHRA) has now authorised oral semaglutide for weight management in adults living with obesity, or those who are overweight with at least one weight-related condition. It contains the same active ingredient used in the injectable Wegovy pen, designed to regulate appetite by mimicking the body’s natural GLP-1 hormone, which helps control hunger and fullness.
In simple terms, it works through the same biological pathway as the injection, but in a daily tablet rather than a weekly injection.
For many patients, that alone will matter. Needle-free treatment removes one of the most common barriers I see in practice: reluctance or anxiety around injections. This could open the door to people who have previously declined treatment, even when clinically eligible.
For those already using GLP-1 injections, the tablet introduces choice rather than replacement. Some patients may prefer the idea of a daily routine over a weekly injection, while others who are stable on treatment are likely to stay with what already works for them. What is clear is that clinicians now have more flexibility to tailor treatment to individual preference and lifestyle.
However, the tablet is not simply a more convenient version of the injection. Oral semaglutide has strict dosing requirements to ensure it is absorbed properly, typically taken on an empty stomach with water and followed by a waiting period before eating. In practice, that means routine and discipline are just as important as the medicine itself.
Clinical trial data supporting regulatory approval show that oral semaglutide can deliver meaningful weight loss when used alongside diet and lifestyle changes. While injectable GLP-1 treatments may still offer slightly higher or more consistent results in some cases, the overall effectiveness is broadly comparable, particularly when patients adhere to treatment correctly.
Side effects are similar across both forms, especially during dose escalation. Nausea, constipation, diarrhoea and abdominal discomfort are the most commonly reported, though these often improve over time as the body adjusts.
From a wider healthcare perspective, this approval is likely to increase demand significantly. Patients who were previously hesitant may now consider treatment, while private clinics and pharmacies will need to adapt to rising interest in GLP-1 therapies more broadly.
The NHS will also need to assess how oral semaglutide fits into existing weight management pathways, including cost-effectiveness and prioritisation alongside injectable options. For patients, however, the arrival of the Wegovy tablet ultimately means more choice.
For more information about Quick Meds, visit https://www.quickmeds.co.uk/online-clinic/weight-loss/
ENDS